PolarityTE logo
PolarityTE PTE

Quarterly report 2023-Q1
added 05-12-2023

report update icon

PolarityTE Income Statement 2011-2026 | PTE

Annual Income Statement PolarityTE

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

4.32 M 41.6 M 23.2 M 75.4 M 226 M 135 M 6.77 M 8.25 M 4.37 M 25.4 M 36.8 M 107 M

Shares

6.85 M 3.2 M 25 M 25 M 15.3 M 4.92 M 2.1 M 1.23 M 1.07 M 991 K 952 K 917 K

Historical Prices

0.63 13 23.2 77.5 443 532 95.2 113 178 560 633 2.63 K

Net Income

-7.83 M -30.2 M -42.9 M -92.5 M -65.4 M -131 M -4.64 M -3.81 M -16.2 M -12.6 M 4.61 M 6.83 M

Revenue

814 K 9.4 M 10.1 M 5.65 M 1.56 M - 1.54 M 6.69 M 34.4 M 47.3 M 132 M 125 M

Cost of Revenue

616 K 4.32 M 4.42 M 2.48 M 1.38 M - 286 K 3.42 M 28.7 M 35.1 M 88.8 M 79.8 M

Gross Profit

198 K 5.09 M 5.7 M 3.17 M 561 K - 1.26 M 3.27 M 5.7 M 12.2 M 43.5 M 45.5 M

Operating Income

-22.4 M -33.7 M -45.9 M -93.4 M -75.1 M -131 M -4.1 M -3.93 M -13.3 M -12.2 M 3.71 M 11.4 M

Interest Expense

-11 K -127 K -182 K 151 K - - - - - - - -

EBITDA

-20.9 M -31 M -38.8 M -90.4 M -68 M -130 M -4.88 M -3.02 M -12.2 M -10.4 M 5.5 M 13.3 M

Operating Expenses

- - 47.8 M 96.6 M 70 M 131 M 6.16 M 6.36 M 18.6 M 23 M 38.6 M 32.6 M

General and Administrative Expenses

15 M 20.5 M 27.6 M 63.2 M 48.3 M 18.8 M 6.03 M 5.35 M 8.37 M 9.18 M 10.1 M 10.5 M

All numbers in USD currency

Quarterly Income Statement PolarityTE

2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

7.32 M 7.26 M 7.22 B 5.15 M 3.36 M 3.3 M 3.25 B 3.22 M 76.2 M 54.9 M 38.8 B 38.4 M 33 M 27.4 M 26.4 M 24.8 M 21.6 M 21.3 M 21.2 M 18.9 M 9.38 M 6.5 M 4.53 M 5.57 M 4.7 M 1.67 M 1.96 M 2.63 M 1.88 M 6.52 M 1.16 M 7.78 M 6.61 M 44.7 M 6.4 M 6.21 M 6.4 M 40.5 M 5.79 M 5.8 M 40.5 M 39.7 M 39.9 M 39.9 M 39.8 M 37.6 M 38.2 M 38.8 M 38.1 M

Net Income

-4.24 M - -3.4 M -68 K -3.77 M - -1.02 M -3.19 M -17.4 M - -7.08 M -12.7 M -13 M - -23 M -22.8 M -25.6 M -18.4 M -20.6 M -14 M -11.8 M -10.9 M -121 M -5.2 M -110 M -647 K -4.23 M -2.49 M -1.1 M -1.16 M -3.02 M -265 K -265 K -4.51 M -10.8 M -2.73 M -3.58 M -2.14 M -8.06 M -3.64 M -2.27 M 7.73 M -2.73 M -3.09 M 2.7 M 6.76 M -3.89 M 1.89 M 2.08 M

Revenue

- - 814 K 73 K 741 K - 1.12 M 2.54 M 4.71 M - 3.34 M 2.27 M 933 K - 1.4 M 1.33 M 1.46 M 673 K 725 K 416 K 3 K 13 K - - 259 K 591 K - 315 K 412 K 3.47 M 6.27 M 1.09 M 1.09 M 21.9 M 28.1 M 2.91 M 3.24 M 23.5 M 37.2 M 4 M 9.72 M 66.2 M 26.6 M 9.14 M 30.4 M 48.5 M 25.1 M 19.5 M 32.1 M

Cost of Revenue

- - 616 K 125 K 491 K - 634 K 924 K 2.16 M - 1.35 M 882 K 516 K - 645 K 596 K 776 K 381 K 667 K 166 K 1 K 1 K - - - 58 K - 92 K 125 K 2.11 M 3.39 M 367 K 367 K 18.5 M 23.5 M 1.77 M 3.18 M 16.3 M 25.8 M 2.76 M 6.68 M 43.2 M 67 M 5.63 M 18.2 M 28.8 M 58.9 M 11.6 M 18.5 M

Gross Profit

- - 198 K -52 K 250 K - 482 K 1.61 M 2.54 M - 1.98 M 1.38 M 417 K - 750 K 730 K 689 K 292 K 58 K 154 K 2 K 12 K - - 259 K 533 K - 223 K 287 K 1.36 M 2.88 M 724 K 724 K 3.39 M 4.59 M 1.14 M 61 K 7.15 M 11.4 M 1.24 M 3.04 M 23 M 4.81 M 3.52 M 12.2 M 19.6 M 4.24 M 7.95 M 13.7 M

Operating Income

-4.8 M - -5.4 M -6.73 M -8.87 M - -7.41 M -8.63 M -8.21 M - -8.58 M -11.1 M -17.7 M - -23.2 M -23.1 M -25.8 M -18.5 M -20.8 M -14.1 M -13.1 M -12.9 M -121 M -5.27 M -110 M -654 K -3.53 M -1.88 M -1.08 M -967 K -3.06 M -734 K -734 K -4.1 M -9.79 M -2.31 M -3.38 M -1.97 M -7.77 M -3.6 M -2.2 M 7.56 M -2.99 M -3.61 M 2.76 M 8.04 M -2.95 M 938 K 5.33 M

Interest Expense

31 K - -4 K -14 K -15 K - -29 K -39 K -38 K - -58 K -65 K -12 K - 27 K 29 K 70 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-4.65 M - -5.03 M -6.33 M -8.42 M - -6.76 M -7.89 M -7.51 M - -7.8 M -10.3 M -17 M - -22.4 M -22.3 M -25.1 M -18.2 M -19.7 M -13.4 M -12.8 M -12.8 M -121 M -5.1 M -110 M -647 K -3.53 M -1.87 M -1.07 M -927 K -3 M -727 K -727 K -4.02 M -9.48 M -2.19 M -3.27 M -1.86 M -7.48 M -3.51 M -2.1 M 7.71 M -2.54 M -3.47 M 2.91 M 8.08 M -2.73 M 1.06 M 5.39 M

Operating Expenses

- - - - - - - - - - - - - - - - - 17.5 M - - 11.6 M 5.22 M - 5.27 M 110 M 1.19 M 3.53 M 1.88 M 1.36 M 2.32 M 5.94 M 1.46 M 1.46 M 7.49 M 14.4 M 3.45 M 3.44 M 9.12 M 19.2 M 4.84 M 5.23 M 15.5 M 32 M 7.13 M 9.41 M 11.6 M 26.9 M 7.02 M 8.32 M

General and Administrative Expenses

2.46 M - 2.68 M 3.56 M 6.21 M - 3.69 M 4.94 M 6.37 M - 6.26 M 5.21 M 10.6 M - 16 M 15.1 M 17.2 M 12.6 M 15.1 M 11.3 M 7.57 M 7.98 M 12.8 M 3.63 M 5.69 M 1.12 M 3.53 M 1.88 M 1.32 M 1.74 M 4.19 M 1.14 M 1.14 M 2.11 M 5.9 M 2 M 1.79 M 2.25 M 6.85 M 2.38 M 2.22 M 3.02 M 8.09 M 2.39 M 2.68 M 3.31 M 8.09 M 2.48 M 2.3 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company PolarityTE (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.25 1.81 % $ 908 M israelIsrael
BioNTech SE BioNTech SE
BNTX
$ 91.28 0.11 % $ 27.2 B germanyGermany
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 330.34 3.6 % $ 43.3 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 0.44 -16.64 % $ 5.04 M israelIsrael
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.98 1.17 % $ 3.05 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 10.14 -0.29 % $ 135 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.58 - $ 106 M usaUSA
Curis Curis
CRIS
$ 0.53 -3.07 % $ 6.98 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 37.7 1.26 % $ 3.55 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 49.15 -0.73 % $ 4.42 B schweizSchweiz
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 2.96 -1.0 % $ 252 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
$ 4.4 -3.51 % $ 607 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
$ 0.86 0.67 % $ 5.79 M usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 0.18 -1.61 % $ 17.1 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.09 -0.97 % $ 437 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 4.15 -32.52 % $ 10.4 M usaUSA
Daré Bioscience Daré Bioscience
DARE
$ 1.81 4.02 % $ 20.2 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 20.36 -3.32 % $ 2.84 B franceFrance
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.22 2.37 % $ 225 M israelIsrael
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 19.38 -6.15 % $ 3.19 B usaUSA
Dyadic International Dyadic International
DYAI
$ 0.87 -2.8 % $ 31.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 31.37 1.0 % $ 2.08 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA